✦ LIBER ✦

36 Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB)

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Resistance surveillance of HBEAG— chroni

✍ S. Xiong; H. Yang; C.E. Westland; W.E. Delaney IV; D. Colledge; A. Bartholomeusz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 162 KB

57 Long-term incidence of adefovir dipiv

✍ X. Qi; A. Snow; V. Thibault; Y. Zhu; M. Curtis; S.J. Hadziyannis; C.L. Brosgart; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Adefovir dipivoxil (ADV) for the treatme

✍ F. Zoulim; C. Trepo; T. Poynard; S. Pol; J.P. Zarski; P. Marcellin; M. Beaugrand 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Predicting HBEAG loss by HBV DNA early k

✍ A.U. Neumann; Y. Havlin; T. Ronen; M. Tsiang; M. Wulfsohn; C. Brosgart; J. Fry; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 148 KB

740 Emergence of dual-resistance HBV mut

✍ S.Y. Kwon; C.H. Lee; W.H. Choi; J.E. Yeon; K.S. Byun 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 239 KB

496 Efficacy and safety of 2 years adefo

✍ M.D. Zeng; Y.M. Mao; G.B. Yao; H. Wang; J.L. Hou; Y.Z. Wang; J.S. Dixon; K.E. Ba 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 116 KB